KN510713 with mFOLFIRINOX for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 to 75 years old
- You have pancreatic cancer (adenocarcinoma) that cannot be removed by surgery or has spread to other parts of the body, and you are scheduled to get the chemotherapy mFOLFIRINOX
- You have not had chemotherapy for advanced pancreatic cancer (prior treatment before or after surgery is okay if more than 6 months since last dose)
- You are able to do daily activities with little to no help (ECOG 0 or 1)
- You have adequate organ function (kidney, liver, blood, and clotting) based on blood tests
- You do not have a known DPD deficiency, specific UGT1A1 genetic variants, or fructose intolerance
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
This trial tests whether giving a strong chemotherapy combination (mFOLFIRINOX) together with radiation therapy can help people with advanced pancreatic cancer who have normal CA19-9 levels. It aims to see if this approach is more effective for this specific group of patients.
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
Hear when a new Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.